Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer

BACKGROUND: Abiraterone acetate (abiraterone) prolongs overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC). This study's objective was to retrospectively identify factors associated with prostate-specific antigen (PSA) response to abiraterone and valid...

詳細記述

保存先:
書誌詳細
出版年:Ann Oncol
主要な著者: Leibowitz-Amit, R., Templeton, A. J., Omlin, A., Pezaro, C., Atenafu, E. G., Keizman, D., Vera-Badillo, F., Seah, J.-A., Attard, G., Knox, J. J., Sridhar, S. S., Tannock, I. F., de Bono, J. S., Joshua, A. M.
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2014
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4433513/
https://ncbi.nlm.nih.gov/pubmed/24458472
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdt581
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料